Aptamer News and Research

RSS

Aptamers for Targeting SARS-CoV-2 Proteins

AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.

From AMS Biotechnology 15 Sep 2021

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

Aptamer Group Ltd and Bio-Works Technologies AB today announce that they have entered into an agreement to co-develop a new affinity resin.

From Aptamer Group 26 Aug 2021

SARS-CoV-2 detection by machine learning surface-enhanced Raman spectroscopy

Surface-enhanced Raman spectroscopy is a highly sensitive molecule characterization method, significantly more sensitive than ordinary Raman spectroscopy due to the excitation of Raman modes matching the plasmon resonance frequency of the surface metal utilized, usually gold, silver, or copper.

11 Aug 2021

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer™ enabled therapeutics

Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.

From Aptamer Group 23 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Aptamer Group Ltd appoints Jordan Clark as Chief Commercial Officer

Aptamer Group, the developer of Optimer biotherapeutics and diagnostics, is pleased to announce the appointment of Jordan Clark as Chief Commercial Officer at Aptamer Group with immediate effect.

From Aptamer Group 10 Jun 2021

Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates

Aptamer Group Limited and PinotBio today announce that they have entered into a strategic collaboration agreement.

From Aptamer Group 2 Jun 2021

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Aptamer Group today announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda.

From Aptamer Group 28 May 2021

Novel molecule could offer a new way to fight against SARS coronavirus 2

Scientists at the University of Bonn and the caesar research center have isolated a molecule that might open new avenues in the fight against SARS coronavirus 2. The active ingredient binds to the spike protein that the virus uses to dock to the cells it infects.

27 Mar 2021

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.

From Aptamer Group 18 Mar 2021

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. Image credit: Shutterstock.com/Billion Photos

From Aptamer Group 5 Mar 2021

Small wearable sensor can detect stress biomarker in sweat

We've all felt stressed at some point, whether in our personal or professional lives or in response to exceptional circumstances like the COVID-19 pandemic. But until now there has been no way to quantify stress levels in an objective manner.

6 Feb 2021

Pioneering diagnostics platform changes the way COVID-19 is detected

Montreal-based Two-Photon Research Inc. announces CAST, a diagnostics platform that changes the way viruses are detected. The CAST platform uses TPR’s patented Aptamer Molecular Photonic Beacon™ that photonically interfaces with smartphones.

10 Dec 2020

UCI researchers develop noninvasive, at-home saliva test to detect COVID-19

Researchers in the Henry Samueli School of Engineering at the University of California, Irvine announced promising results in the development of a noninvasive at-home antigen test to detect the spike of SARS-CoV-2 proteins in saliva.

9 Dec 2020

Researchers find a new therapeutic approach to combat leukemia

Leukemia frequently originates from the so-called leukemic stem cell, which resides in a tumor promoting and protecting niche within the bone marrow. Scientists from the Max Planck Institute of Biochemistry in Martinsried, Germany, have found a new way to make these cells vulnerable by specifically dislodging these cells from their niches.

23 Oct 2020

New optical switch to precisely control the lifespan of genetic 'copies'

A novel optical switch makes it possible to precisely control the lifespan of genetic "copies". These are used by the cell as building instructions for the production of proteins.

25 Sep 2020

Brazilian startup to develop a low-cost high-performance COVID-19 diagnostic test

Researchers at Biolinker, a biotech startup based in São Paulo, Brazil, are developing a low-cost high-performance COVID-19 diagnostic test using only locally sourced inputs.

26 Jun 2020

Study shows antihypertensive drugs do not raise serum levels of ACE2

A new study published on the preprint server medRxiv* by researchers from Iceland and the U.S. shows how treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) does not raise angiotensin-converting enzyme 2 (ACE2) levels in human serum – and cautions against the discontinuation of these drugs among patients affected with coronavirus disease (COVID-19).

26 May 2020

Study finds race-specific lupus nephritis biomarkers for early diagnosis, treatment

University of Houston Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, Chandra Mohan, and his team have discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

6 May 2020

Researchers re-purpose cancer-fighting artificial antibodies for COVID-19

Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.

27 Apr 2020